<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="696">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375124</url>
  </required_header>
  <id_info>
    <org_study_id>KSSEAH--0059</org_study_id>
    <nct_id>NCT04375124</nct_id>
  </id_info>
  <brief_title>Treatment of Angiotensin Peptide (1-7) for COVID-19</brief_title>
  <official_title>Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kanuni Sultan Suleyman Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kanuni Sultan Suleyman Training and Research Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses
      ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the
      activity of ACE 2. Upon these data the investigators hypothesize that, mortal
      hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin
      peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect
      of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses
      ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the
      activity of ACE 2. Upon these data the investigators hypothesize that, mortal
      hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin
      peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect
      of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This group will receive angiotensin peptide (1-7) during their treatment at hospital.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mortality</measure>
    <time_frame>4 months</time_frame>
    <description>mortality rates in two groups will be compared</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>non-peptide group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group will receive routine treatment and care for COVID-19.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>peptide group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive angiotensin peptide (1-7) supplementation in addition to routine treatment and care for COVID-19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Biological/Vaccine: Angiotensin peptide (1-7) derived plasma</intervention_name>
    <description>angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants</description>
    <arm_group_label>peptide group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  accepted to participate with an informed consent

          -  proven positive COVID-19

        Exclusion Criteria:

          -  declined to participate

          -  genetic/chromosomal abnormalities

          -  any kind of history of previous adverse events with transfusion

          -  diagnosis of immune deficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hasan Onal</last_name>
    <phone>+905325092988</phone>
    <email>hasanonal@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seda Yilmaz Semerci</last_name>
    <phone>+905337180683</phone>
    <email>sedayilmazsemerci@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kanuni Sultan Suleyman Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <zip>34303</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hasan Onal</last_name>
      <phone>+905325092988</phone>
      <email>hasanonal@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kanuni Sultan Suleyman Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Hasan Onal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

